These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 17575218)

  • 1. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma.
    Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T
    Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of 18F-FDG PET for the assessment of early response to the treatment and prognosis of patients].
    Oriuchi N; Higuchi T; Endo K; Tsukamoto N; Matsuda H; Kuji I; Murakami K; Nakajima K
    Kaku Igaku; 2009 Jun; 46(2):96-9. PubMed ID: 19637820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of 3'-deoxy-3'-[18F]fluorothymidine PET/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma.
    Lawrence J; Vanderhoek M; Barbee D; Jeraj R; Tumas DB; Vail DM
    Vet Radiol Ultrasound; 2009; 50(6):660-8. PubMed ID: 19999354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
    Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
    J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Resulting Changes in Volumes of High-
    Huang YM; Hsieh CH; Wang SY; Tsao CH; Lee JC; Chen YJ
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of R-CHOP chemotherapy on liver and mediastinal blood pool (18)F-FDG standardized uptake values in patients with non-Hodgkin's lymphoma.
    Kaya B; Dostbil Z; Ismailoglu M; Tasdemir B; Sahin O
    Clin Imaging; 2015; 39(4):632-5. PubMed ID: 25709112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study.
    Buchmann I; Neumaier B; Schreckenberger M; Reske S
    Cancer Biother Radiopharm; 2004 Aug; 19(4):436-42. PubMed ID: 15453958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effective immunochemotherapy for aggressive non-Hodgkin's lymphoma.
    Coiffier B
    Semin Oncol; 2004 Feb; 31(1 Suppl 2):7-11. PubMed ID: 15042528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Week one FLT-PET response predicts complete remission to R-CHOP and survival in DLBCL.
    Herrmann K; Buck AK; Schuster T; Abbrederis K; Blümel C; Santi I; Rudelius M; Wester HJ; Peschel C; Schwaiger M; Dechow T; Keller U
    Oncotarget; 2014 Jun; 5(12):4050-9. PubMed ID: 24979177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary non-Hodgkin lymphoma of cervix successfully treated with rituximab: positron emission tomography images before and after therapy: a case report.
    Ustaalioglu BB; Bilici A; Seker M; Canpolat N; Ozdemir N; Salepci T; Gumus M
    Leuk Res; 2010 Apr; 34(4):e108-10. PubMed ID: 19931906
    [No Abstract]   [Full Text] [Related]  

  • 12. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
    Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
    Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy.
    Phan J; Mazloom A; Medeiros LJ; Zreik TG; Wogan C; Shihadeh F; Rodriguez MA; Fayad L; Fowler N; Reed V; Horace P; Dabaja BS
    J Clin Oncol; 2010 Sep; 28(27):4170-6. PubMed ID: 20713859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical comparison of CHO regimen versus CHOP regimen for treatment of patients with intermediate-grade non-Hodgkin's lymphoma].
    Yuan ZY; Xu RH; He YJ; Guan ZZ
    Ai Zheng; 2003 Apr; 22(4):393-6. PubMed ID: 12703996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
    Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
    Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
    Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sarcoid-like reaction in the spleen following chemotherapy for non-Hodgkin's lymphoma.
    Reilly TB; Schuster DM; Starsiak MD; Kost CB; Halkar RK
    Clin Nucl Med; 2007 Jul; 32(7):569-71. PubMed ID: 17581351
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.